Skip to main content
Pharnext logo

Pharnext — Investor Relations & Filings

Ticker · ALPHA ISIN · FR0011191287 LEI · 969500KJGF9ZUYXSMJ27 Euronext Growth Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2023-11-27 Regulatory Filings
Country FR France
Listing Euronext Growth ALPHA

About Pharnext

https://pharnext.com/

Pharnext is an advanced clinical-stage biopharmaceutical company that develops novel therapeutics for neurodegenerative diseases lacking curative or satisfactory treatments. The company's approach is based on its proprietary Pleotherapy™ platform, which uses network pharmacology to identify and develop synergistic combinations of already-approved drugs at new, lower doses. This strategy aims to create more effective and safer treatments. Pharnext's lead product candidate, PXT3003, is an oral fixed-dose combination therapy in development for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating inherited peripheral neuropathy.

Recent filings

Filing Released Lang Actions
Pharnext dévoile le nouveau calendrier de négociations en vue de valoriser son candidat médicament dans la maladie de Charcot-Marie-Tooth de type 1A
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces an update regarding the negotiation timeline for valuing the drug candidate PXT3003, specifically delaying the signing of an exclusivity agreement until after the Phase III clinical trial results are published on December 11th. This is a strategic business update concerning potential financing/licensing deals and upcoming data releases. It is not a full financial report (10-K or IR), an earnings release (ER), or a formal regulatory filing like a DVA or DIRS. Since it is a specific announcement about business strategy, financing potential, and upcoming data, it best fits the category for Capital/Financing Updates (CAP) or potentially a general Regulatory Filing (RNS) if CAP is too narrow. However, the core message is about structuring a major financial/licensing deal contingent on clinical data, which strongly aligns with 'Capital/Financing Update' (CAP). Given the context of ongoing negotiations for asset valuation, CAP is the most precise fit over the general RNS.
2023-11-27 French
Pharnext unveils new calendar for negotiations valuing its drug candidate in Charcot-Marie-Tooth disease type 1A
Capital/Financing Update Classification · 1% confidence The document is a press release dated November 27, 2023, announcing an update regarding negotiations for valuing the drug candidate PXT3003. It discusses offers received, the decision to wait for Phase III clinical trial results (planned for December 11), and mentions financing arrangements (OCEANE-BSA line). This content relates to potential future financing, licensing deals, and corporate strategy surrounding a key asset, which falls under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if it were a general announcement. However, the core subject is the negotiation process for a major transaction (licensing/sale) that directly impacts the company's capital structure and future cash flow, as it explicitly states: 'The signature of such agreements could cover Pharnext's financing needs'. This strongly aligns with the definition of Capital/Financing Update (CAP). It is not an Earnings Release (ER), Interim Report (IR), or a formal 10-K. Since it is a specific announcement about financing/deal structuring, CAP is the most appropriate specific code over the general RNS.
2023-11-27 English
Levée de fonds de 0,5 million d'euros
Share Issue/Capital Change Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific financial transaction: a fundraising effort ("Levée de fonds de 0,5 million d'euros") through the issuance of convertible bonds with warrants (OCEANE-BSA). This directly relates to the company's capital structure and fundraising activities. Based on the definitions, the most appropriate category is 'Capital/Financing Update' (CAP). Although it is a press release, the core content is the financing event itself, not just an announcement of a report (which would suggest RPA or RNS).
2023-11-24 French
Pharnext announces being at D-18 before publication of topline results from pivotal Phase III clinical trial (PREMIER trial) in Charcot-Marie-Tooth disease type 1A
Regulatory Filings Classification · 1% confidence The document is a press release announcing a future event: the publication of topline results from a clinical trial (PREMIER trial) expected on December 11th, 2023. It details the timeline for data lock and preliminary analysis. This type of announcement, which communicates key operational or clinical milestones without releasing the full financial results or a formal regulatory report, is best classified as a general announcement. Since it is not a formal Earnings Release (ER), Interim Report (IR), or a specific regulatory filing like 10-K, and it is not announcing the publication of a report (RPA), the most appropriate general category for significant corporate updates that don't fit elsewhere is Regulatory Filings (RNS), which often serves as a catch-all for important, non-standard announcements, especially in European contexts where RNS is common for market information dissemination. Given the context of clinical trial updates, it is a significant corporate event announcement.
2023-11-23 English
Pharnext annonce être à J-18 de la publication des premiers résultats de l'étude clinique pivot de Phase III (essai PREMIER) dans la maladie de Charcot-Marie-Tooth de type 1A
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a future event: the upcoming publication of Phase III clinical trial results (PREMIER trial) for PXT3003 in CMT1A, scheduled for December 11, 2023. It details the timeline, the study design, and provides background information on the disease and the company. This type of announcement, which communicates key operational or clinical milestones via a press release format, typically falls under a general regulatory announcement or an update related to ongoing operations, but it is not the full financial report (10-K, IR), the earnings release (ER), or the presentation of results (IP). Since it is a formal announcement of a significant corporate/clinical event, and it doesn't fit the specific categories like M&A (TAR), Capital (CAP), or Director Dealing (DIRS), the most appropriate classification is the general regulatory announcement category, RNS, as it serves as a broad communication to the market about a material event. It is not an announcement *of* a report publication (RPA), but the content itself is the news item.
2023-11-23 French
Pharnext annonce avoir réussi la fabrication des lots d'enregistrement de PXT3003 aux États-Unis
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific operational milestone: the successful manufacturing of registration batches for PXT3003 in the US, which is a step towards filing a New Drug Application (NDA) with the FDA. It also mentions upcoming clinical data releases and includes a significant warning about dilutive financing. This content is characteristic of an immediate, material announcement to the market, rather than a comprehensive periodic report (like 10-K or IR) or a formal regulatory filing document itself. Since it is a press release detailing operational progress and future expectations, it best fits the category of an Earnings Release (ER) if it were tied to financial results, but since it is focused on operational/clinical progress and is a general announcement, the most appropriate general category for immediate, non-periodic, material news that doesn't fit other specific operational/legal categories is Regulatory Filings (RNS) as a catch-all for press releases, or potentially a general announcement related to capital/financing if the focus was solely on the financing warning, but the primary focus is operational progress. Given the options, and that it is a press release announcing key operational progress (manufacturing success, NDA preparation), it is a material announcement. If it were purely financial results, it would be ER. Since it is a general, material announcement that doesn't fit the specific operational/legal/governance codes, RNS (Regulatory Filings/General Announcement) is the best fit, although ER is often used for press releases accompanying results. Since this is a manufacturing/clinical update, RNS is the most suitable fallback for a press release of this nature.
2023-11-20 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.